Patient And Clinician Perceptions Of Disease Improvement With Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) In Advanced Parkinson’s – Data From The ELEGANCE Interim Analysis
Objective: To evaluate clinicians’ and patients’ views of the level of improvement in Parkinson’s disease (PD) achieved following up to two years of treatment with…Safety and tolerability of overnight switching from Eetacapone to Opicapone in fluctuating Parkinson’s disease: An open-label preliminary trial in Koreans
Objective: Objectives: 1. Efficacy - Opicapone 50mg qd. to determine effectiveness of optimal dose for switching. 2. Tolerability and safety - compare symptoms and adverse…Comparative analysis of opicapone and entacapone in the management of motor fluctuations in patients with Parkinson’s disease, from clinical trials to healthcare resource usage
Objective: To assess the differences between two catechol-O-methyltransferase (COMT) inhibitors, opicapone (OPC) and entacapone (ENT). Background: Opicapone and ENT are COMT inhibitors developed as adjunct…Safety and tolerability of opicapone in Parkinson’s Disease: from early-stage (EPSILON study) to late-stage (BIPARK studies)
Objective: To compare the safety and tolerability of once-daily opicapone (OPC) 50mg as add-on to stable levodopa/dopa decarboxylase inhibitor (L-DOPA/DDCI) therapy in patients from early…Opicapone real-world experience in early motor fluctuations: 3-months analysis of the REONPARK study.
Objective: The REONPARK study aims to evaluate COMT inhibitor (iCOMT) effectiveness and tolerability in alleviating motor complications associated with L-dopa treatment in Parkinson’s Disease patients…Adverse Events of Opicapone Adjunctive Therapy in 60 Consecutive Patients
Objective: This study aimed to investigate the risk of adverse events (AEs) when opicapone (OPC) was added as adjunctive therapy to L-dopa administration. Background: Levodopa…Opicapone versus entacapone: Head-to-head comparison of Healthcare Resource Utilisation in COMT-I naïve People with Parkinson’s
Objective: In this retrospective cohort study, we assessed healthcare resource utilisation (HCRU) outcomes in People with Parkinson’s (PwP) naïve to Catechol-O-methyl transferase (COMT) inhibition via…Levodopa-entacapone-carbidopa-infusion treatment in Parkinson’s disease: A six-month follow-up study
Objective: Objectives of this study were to evaluate changes in medication, adverse events and early discontinuations of levodopa-entacapone-carbidopa-intestinal-gel (LECIG) treatment in advanced Parkinson’s disease (PD).…Update on the ADOPTION Study: Randomised, Open-Label Exploratory Trial of Opicapone in Parkinson’s Disease
Objective: This exploratory trial aims to compare treatment outcomes of adding one daily dose of opicapone (OPC) 50 mg versus an additional dose of levodopa…Dyskinesia and adherence to safinamide and opicapone in fluctuating patients with Parkinson’s disease: observational retrospective study
Objective: To assess differences in the new onset or worsening of baseline dyskinesia after the introduction of safinamide (SA) or opicapone (OP) as add-on therapy…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 12
- Next Page »